Pubblicazioni

Autori:

Faber, Erik B; Krause, Harris B; Amin, Khalid; Walker, Philip; Hosein, Peter J; Shields, Anthony F; Lenz, Heinz-Josef; Prakash, Ajay; Goel, Sanjay; Oberley, Matthew; Malleo, Giuseppe; Luchini, Claudio; Hwang, Justin; Florou, Vaia; Garrido-Laguna, Ignacio; Lou, Emil

Titolo:

Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets

Anno:

2024

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

No

Nome rivista:

JCO PRECISION ONCOLOGY

ISSN Rivista:

2473-4284

N° Volume:

8

Intervallo pagine:

1-9

Parole chiave:

undifferentiated sarcomatoid carcinoma (USC), pancreatic ductal adenocarcinoma (PDAC)

Breve descrizione dei contenuti:

Purpose: The highly aggressive undifferentiated sarcomatoid carcinoma (USC) subtype of pancreatic ductal adenocarcinoma (PDAC) remains poorly characterized because of its rarity. Previous case reports suggest that immune checkpoint inhibitors could be a promising treatment strategy, but the prevalence of established predictive biomarkers of response is largely unknown. The objective of this study was to leverage comprehensive genomic profiling of USC PDAC tumors to determine the prevalence of biomarkers associated with potential response to targeted therapies. Methods: USC tumors (n = 20) underwent central pathology review by a board-certified gastrointestinal pathologist to confirm the diagnosis. These samples were compared with non-USC PDAC tumors (N = 5,562). Retrospective analysis of DNA and RNA next-generation sequencing data was performed. Results: USC PDACs were more frequently PD-L1+ by immunohistochemistry than non-USC PDAC (63% v 16%, respectively, P < .001). Furthermore, USC PDAC had an increase in neutrophils (8.99% v 5.55%, P = .005) and dendritic cells (1.08% v 0.00%, q = 0.022) and an increased expression of PDCD1LG2 (4.6% v 1.3%, q = 0.001), PDCD1 (2.0% v 0.8%, q = 0.060), and HAVCR2 (45.9% v 21.7%, q = 0.107) than non-USC PDAC. Similar to non-USC PDAC, KRAS was the most commonly mutated gene (86% v 90%, respectively, P = 1). Conclusion: To our knowledge, this work represents the largest molecular analysis of USC tumors to date and showed an increased expression of immune checkpoint genes in USC tumors. These findings provide evidence for further investigation into immune checkpoint inhibitors in USC tumors.

Id prodotto:

139632

Handle IRIS:

11562/1126387

ultima modifica:

22 agosto 2024

Citazione bibliografica:

Faber, Erik B; Krause, Harris B; Amin, Khalid; Walker, Philip; Hosein, Peter J; Shields, Anthony F; Lenz, Heinz-Josef; Prakash, Ajay; Goel, Sanjay; Oberley, Matthew; Malleo, Giuseppe; Luchini, Claudio; Hwang, Justin; Florou, Vaia; Garrido-Laguna, Ignacio; Lou, Emil, Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets «JCO PRECISION ONCOLOGY» , vol. 8 , 2024 , pp. 1-9

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo